title: Correlation between serum prolactin levels and hepatocellular tumorigenesis induced by 3'-methyl-4-dimethylaminoazobenzene in mice.
abstract: Ovariectomy at 1 month of age promotes development of hepatocellular adenomatous nodules in female C57BL/6 x DS-F1 mice treated neonatally with 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB). Implantation of oestradiol-17 beta (E2) pellets at 1 month of age suppresses nodule development. Since E2 increases serum levels of prolactin, high serum levels of prolactin in mice that have received implants of E2 pellets may play a role in the suppression of hepatocellular tumorigenesis. Therefore, to investigate the role of prolactin in hepatocellular tumorigenesis, we examined development of adenomatous nodules in female mice that had been treated neonatally with 3'-Me-DAB and had undergone ovariectomy at 1 month of age, under various serum levels of prolactin. Treatment of these mice with perphenazine (dopamine antagonist) from 6 months of age or transplantation of pituitary glands under the renal capsule at 6 months of age markedly increased serum levels of prolactin and significantly suppressed the incidence of adenomatous nodules at 12 months of age. Implantation of E2 pellets at 1 month of age increased serum levels of prolactin to a greater extent and further decreased the incidence of adenomatous nodules. Treatment of mice that had received implants of E2 pellets at 1 month of age with bromocriptine (dopamine agonist) from 6 months of age decreased serum levels of prolactin, and was accompanied by an increase in the incidence of nodules. The present results showed that an increase in serum levels of prolactin was accompanied by a decrease in incidence of liver tumours induced by 3'-Me-DAB in mice, suggesting a suppressive effect of prolactin on liver tumorigenesis in mice. Thus, it is possible that the suppressive effect of oestrogen on liver tumorigenesis in mice is mediated, at least in part, by prolactin.
authors.affiliation: Department of Gastrointestinal Oncology, Center for Adult Diseases, Osaka, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Yamamoto
authors.forename: H
authors.initials: H
authors.lastname: Iishi
authors.forename: M
authors.initials: M
authors.lastname: Tatsuta
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Koike
authors.forename: Y
authors.initials: Y
authors.lastname: Kanda
authors.forename: A
authors.initials: A
authors.lastname: Miyake
authors.forename: M
authors.initials: M
authors.lastname: Tsuji
authors.forename: N
authors.initials: N
authors.lastname: Terada
mesh_terms: D000236:Adenoma / Q000517:prevention & control; D000818:Animals; D001971:Bromocriptine / Q000627:therapeutic use; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D008114:Liver Neoplasms, Experimental / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D008749:Methyldimethylaminoazobenzene; D051379:Mice; D008810:Mice, Inbred C57BL; D010546:Perphenazine / Q000494:pharmacology; D010902:Pituitary Gland / Q000637:transplantation; D011388:Prolactin / Q000097:blood*
chemical_list: D004967:Estrogens; D001971:Bromocriptine; D008749:Methyldimethylaminoazobenzene; D011388:Prolactin; D010546:Perphenazine